Saturday, October 1 2022

LONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” Where “small pharmacy), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health disorders, today announced that the TSX Venture Exchange (the “TSXV”) accepted the Company’s application for its normal course issuer bid (the “ORCN”) for up to five million ordinary shares (“Shares”) in the capital of the Company, representing 1.55% of the issued and outstanding Shares, over a period of 12 months.

The NCIB is scheduled to begin on August 19, 2022 and run until August 18, 2023 (the “Termination date”) or earlier in the event that the Company has acquired the maximum number of Shares that it may purchase under the OPRA or if the Company determines that it is appropriate to terminate the OPRA before the termination. The actual number of shares that will be purchased under the issuer bid, if any, and the timing of such purchases will be determined by the Company from time to time. All purchases made under the issuer bid will be made through the facilities of the TSXV in open market transactions or by any other means permitted under applicable securities laws. and policies of TSXV. All Shares purchased under the OPRA will be cancelled.

The Company has retained Eight Capital as broker through which the Company will make purchases under the issuer bid in accordance with the policies of the TSXV. The price that the Company will pay for the shares purchased under the issuer bid, if any, will be the market price of such shares at the time of the applicable purchases.

George Tziras, CEO of Small Pharma, said, “We believe that the current market price of our common shares does not adequately reflect their value. The Company takes a prudent and responsible approach to preserving cash and we believe that the purchase of Common Shares under the Tender Bid will be in the best interest of the Company and enhance shareholder value. .

To the knowledge of the Company, no director, senior officer or other insider of the Company currently intends to sell shares under the issuer bid.

About Small Pharma
Small Pharma is a biotechnology company developing a pipeline of short-acting psychedelics with therapy for the treatment of mental health issues, with a particular focus on depression. Small Pharma has initiated a clinical program on N,N-dimethyltryptamine (“DMT”) assisted psychotherapy in February 2021. This program includes a Phase I/IIa trial on the Company’s lead candidate as well as the development of a pipeline of proprietary preclinical assets.

About DMT
DMT is a naturally occurring psychedelic tryptamine found in plants and mammalian brains. Scientific evidence suggests that DMT offers the potential for fast-acting, long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (

For more information, contact:

Petite Pharma Inc.
George Tziras, Managing Director
E-mail: [email protected]
Tel: +1 (646) 751-4363

Investor Relations Contacts:
Eric Ribner
LifeSci Advisors
E-mail: [email protected]
Such. : +1 (646) 889-1200

Kristi Papanikolaw
KCSA Strategic Communications
E-mail: [email protected]
Tel: +1 (347) 487-6181

Contacts for Media Relations:
United States – McKenna Miller
KCSA Strategic Communications
Email: [email protected]
Tel: +1 (949) 949-6585

Rest of the world – Jaber Mohamed
MHP Communications
E-mail: [email protected]
Tel: +44 (0)7720 326 847

Caution Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical facts, are forward-looking information and are based on expectations, estimates and projections as of the date of this press release. Any statement that discusses predictions, expectations, beliefs, plans, projections, goals, assumptions, future events, or performance (often, but not always, using expressions such as “s’ expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “plans”, “estimates”, “believes” or “intends” or variations of these words and phrases or indicating that certain actions, events or results “may” or “might”, “would”, “might” or “will” be assumed to occur or be realized) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this press release include statements regarding the price and number of shares that may be purchased under the tender offer.

In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it cannot guarantee that the expectations in such forward-looking information will prove to be correct. Known and unknown risks, uncertainties and other factors that may cause actual results and future events to differ materially from those expressed or implied by such forward-looking information. These factors include, but are not limited to: compliance with numerous government regulations; domestic and foreign laws and regulations adversely affecting the Company’s business and results of operations; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and undertakes no obligation to update or revise forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting this forward-looking information. -search for information or other.

Small Pharma makes no medical, treatment or health benefit claims regarding the products it offers. The UK Medicines and Health Products Regulatory Agency (“MHRA”) or other similar regulatory authorities have not evaluated claims regarding DMT-assisted therapies and other next-generation psychoactive compounds. The effectiveness of such therapies has not been confirmed by MHRA-approved research. There is no guarantee that these therapies assisted by DMT and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Any reference to the quality, consistency, efficacy and safety of potential therapies does not imply that Small Pharma has verified it in clinical trials or that Small Pharma will complete such trials. Failure by Small Pharma to obtain the necessary approvals or research to commercialize its business could have a material adverse effect on Small Pharma’s performance and operations.

The TSXV has neither approved nor disapproved of the contents of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Previous

CANACCORD GENUITY GROUP INC. DISCLOSES ORDINARY COURSE ENTRY OFFER

Next

Fixed Income Trader: Job Description and Salary

Check Also